{"links":{"html":"https://www.erudio.com/reports/rosetta-lung-02-nct06712316","json":"https://www.erudio.com/reports/rosetta-lung-02-nct06712316.json","markdown":"https://www.erudio.com/reports/rosetta-lung-02-nct06712316.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"rosetta-lung-02-06712316"}},"request":"https://www.erudio.com/contact?report=rosetta-lung-02-06712316"},"offer":{"cited_commentary_sources":31,"verified_hcp_statements":146,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":13,"optional":true,"price_per_verified_person_usd":15,"price_usd":195,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"rosetta-lung-02-nct06712316"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=rosetta-lung-02-06712316","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/rosetta-lung-02-nct06712316","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-02T02:32:01.211776Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":17,"no_commentary_found":1},"aspects":[{"claim_count":6,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":6,"title":"Primary endpoint: Phase 2 - Occurrence of treatment-emergent adverse events (TEAE) (including Grade ≥3), adverse events of special interest (AESIs), treatment-related TEAEs, treatment-emergent serious adverse events (SAE), and treatment-related treatment emergent SAEs"},{"claim_count":4,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":4,"title":"Primary endpoint: Phase 2 - Occurrence of dose interruption, reduction, and discontinuation of IMP due to TEAEs (including related TEAEs)"},{"claim_count":20,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.primaryOutcomes[2]","source_count":16,"title":"Primary endpoint: Phase 2 - Objective response rate (ORR)"},{"claim_count":3,"coverage":"discussed","id":"T4","registry_field":"outcomesModule.primaryOutcomes[3]","source_count":1,"title":"Primary endpoint: Phase 2 - Best percentage change from baseline in tumor size"},{"claim_count":0,"coverage":"no_commentary_found","id":"T5","registry_field":"outcomesModule.primaryOutcomes[4]","source_count":0,"title":"Primary endpoint: Phase 3 - Progression free survival (PFS) assessed by BICR"},{"claim_count":11,"coverage":"discussed","id":"T6","registry_field":"outcomesModule.secondaryOutcomes","source_count":6,"title":"Secondary endpoints"},{"claim_count":28,"coverage":"discussed","id":"T7","registry_field":"conditionsModule","source_count":11,"title":"Population and setting"},{"claim_count":15,"coverage":"discussed","id":"T8","registry_field":"armsInterventionsModule.armGroups","source_count":10,"title":"The comparison"},{"claim_count":20,"coverage":"discussed","id":"T9","registry_field":"outcomesModule","source_count":8,"title":"Safety and tolerability"},{"claim_count":12,"coverage":"discussed","id":"T10","registry_field":"designModule","source_count":8,"title":"Design and conduct"},{"claim_count":13,"coverage":"discussed","id":"A1","source_count":8,"title":"PD-L1 breadth, biomarker selection and avoiding nonbeneficial treatment"},{"claim_count":28,"coverage":"discussed","id":"A2","source_count":5,"title":"Cooperative binding, molecular architecture and PD-L2 trade-offs"},{"claim_count":11,"coverage":"discussed","id":"A3","source_count":2,"title":"Bleeding concerns, vessel involvement and multidisciplinary imaging review"},{"claim_count":5,"coverage":"discussed","id":"A4","source_count":5,"title":"Dose optimization and exploratory ctDNA"},{"claim_count":24,"coverage":"discussed","id":"A5","source_count":6,"title":"Class comparisons, global validation and evidence maturity"},{"claim_count":9,"coverage":"discussed","id":"A6","source_count":2,"title":"ADC alternatives, combination strategies and supportive-care feasibility"},{"claim_count":9,"coverage":"discussed","id":"A7","source_count":3,"title":"Durable survival, cure language and accessible patient interpretation"},{"claim_count":22,"coverage":"discussed","id":"A8","source_count":18,"title":"Development expectations, research access and nonclinical reactions"}],"counts":{"cited_sources":31,"claims_by_expression_type":{"comparison":13,"experience":1,"interpretation":54,"opinion":37,"primary_context":1,"question":6,"restatement":15,"uncertainty":8,"unspecified":11},"claims_by_kind":{"source_observation":146},"clinician_statements":70,"evidence_units":110,"findings":10,"organisational_accounts":10,"people_cited":17,"people_identity_verified":13,"people_total":17,"screened_sources":71,"verified_claims":146},"findings_index":[{"id":"F1","structure":{"claims":18,"claims_by_group":{"comparisons":1,"experience":0,"questions":3,"restated":4,"views":10},"has_counterview":true,"limitations":2,"links":{"context":0,"support":24},"ma_question":true,"named_voices":7,"passages":15,"sources":9,"sources_by_kind":{"commentary":5,"media":4}},"title":"Can pumitamig improve on the pembrolizumab–chemotherapy backbone?"},{"id":"F2","structure":{"claims":16,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":1,"views":13},"has_counterview":true,"limitations":2,"links":{"context":6,"support":17},"ma_question":true,"named_voices":5,"passages":18,"sources":4,"sources_by_kind":{"commentary":2,"media":2}},"title":"Squamous use, hemoptysis and vessel-involvement concerns"},{"id":"F3","structure":{"claims":14,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":1,"views":12},"has_counterview":true,"limitations":2,"links":{"context":3,"support":14},"ma_question":true,"named_voices":8,"passages":15,"sources":8,"sources_by_kind":{"commentary":4,"media":4}},"title":"PD-L1-negative disease and the search for selection biomarkers"},{"id":"F4","structure":{"claims":11,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":2,"views":8},"has_counterview":true,"limitations":2,"links":{"context":0,"support":12},"ma_question":true,"named_voices":1,"passages":6,"sources":3,"sources_by_kind":{"media":3}},"title":"The frontline interview's comparator account and population restrictions"},{"id":"F5","structure":{"claims":28,"claims_by_group":{"comparisons":2,"experience":0,"questions":8,"restated":4,"views":14},"has_counterview":true,"limitations":2,"links":{"context":12,"support":33},"ma_question":true,"named_voices":4,"passages":29,"sources":4,"sources_by_kind":{"commentary":2,"media":2}},"title":"Does molecular architecture translate into clinical differences?"},{"id":"F6","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":2,"views":5},"has_counterview":false,"limitations":2,"links":{"context":1,"support":8},"ma_question":true,"named_voices":5,"passages":9,"sources":6,"sources_by_kind":{"commentary":3,"media":3}},"title":"Dose selection and exploratory ctDNA interpretation"},{"id":"F7","structure":{"claims":20,"claims_by_group":{"comparisons":6,"experience":0,"questions":1,"restated":6,"views":7},"has_counterview":true,"limitations":3,"links":{"context":9,"support":23},"ma_question":true,"named_voices":2,"passages":5,"sources":2,"sources_by_kind":{"commentary":1,"media":1}},"title":"Class comparisons generate hypotheses, not a fair ranking of agents"},{"id":"F8","structure":{"claims":9,"claims_by_group":{"comparisons":2,"experience":0,"questions":1,"restated":1,"views":5},"has_counterview":true,"limitations":3,"links":{"context":2,"support":10},"ma_question":true,"named_voices":5,"passages":9,"sources":2,"sources_by_kind":{"media":2}},"title":"ADC alternatives, platinum inclusion and day-to-day toxicity management"},{"id":"F9","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":5},"has_counterview":true,"limitations":2,"links":{"context":0,"support":7},"ma_question":true,"named_voices":3,"passages":4,"sources":2,"sources_by_kind":{"media":2}},"title":"Durability, disease stability and the meaning of cure"},{"id":"F10","structure":{"claims":22,"claims_by_group":{"comparisons":1,"experience":1,"questions":0,"restated":5,"views":15},"has_counterview":true,"limitations":3,"links":{"context":3,"support":23},"ma_question":true,"named_voices":12,"passages":19,"sources":18,"sources_by_kind":{"commentary":16,"media":2}},"title":"Anticipation and competitive forecasts should remain distinct from confirmed clinical voices"}],"medical_affairs_question":"What comparative benefit and patient-selection evidence would justify replacing the current backbone without exposing unlikely beneficiaries to avoidable toxicity?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Early activity and the unresolved replacement question"},{"id":"section-2","level":2,"title":"Safety reassurance and bleeding-risk selection"},{"id":"section-3","level":2,"title":"PD-L1 subgroups, unmet need and biomarker selection"},{"id":"section-4","level":2,"title":"Contextual frontline interview: optimism, eligibility and a differing comparator account"},{"id":"section-5","level":2,"title":"Mechanistic confidence and clinical differentiation are different questions"},{"id":"section-6","level":2,"title":"Dose and ctDNA: optimization rather than validation"},{"id":"section-7","level":2,"title":"Cross-trial class themes, global validation and comparator choice"},{"id":"section-8","level":2,"title":"ADC choices: platinum, controls and supportive-care constraints"},{"id":"section-9","level":2,"title":"Durability and patient interpretation are the desired destination"},{"id":"section-10","level":2,"title":"Anticipation, research access and competitive forecasts are different kinds of evidence"},{"id":"section-11","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, sequential, phase2, phase3","trial_dimensions":[{"findings":[{"id":"F2","shared_claims":3},{"id":"F6","shared_claims":1},{"id":"F10","shared_claims":1}],"id":"T1","label":"Primary endpoint: Phase 2 - Occurrence of treatment-emergent adverse events (TEAE) (including Grade ≥3), adverse events of special interest (AESIs), treatment-related TEAEs, treatment-emergent serious adverse events (SAE), and treatment-related treatment emergent SAEs"},{"findings":[{"id":"F2","shared_claims":1},{"id":"F7","shared_claims":1},{"id":"F10","shared_claims":1}],"id":"T2","label":"Primary endpoint: Phase 2 - Occurrence of dose interruption, reduction, and discontinuation of IMP due to TEAEs (including related TEAEs)"},{"findings":[{"id":"F1","shared_claims":6},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":6},{"id":"F6","shared_claims":1},{"id":"F7","shared_claims":2},{"id":"F9","shared_claims":1},{"id":"F10","shared_claims":5}],"id":"T3","label":"Primary endpoint: Phase 2 - Objective response rate (ORR)"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F9","shared_claims":3}],"id":"T4","label":"Primary endpoint: Phase 2 - Best percentage change from baseline in tumor size"},{"findings":[],"id":"T5","label":"Primary endpoint: Phase 3 - Progression free survival (PFS) assessed by BICR"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":1},{"id":"F9","shared_claims":6},{"id":"F10","shared_claims":2}],"id":"T6","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F2","shared_claims":4},{"id":"F3","shared_claims":14},{"id":"F4","shared_claims":6},{"id":"F6","shared_claims":1},{"id":"F7","shared_claims":1},{"id":"F10","shared_claims":1}],"id":"T7","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":9},{"id":"F4","shared_claims":4},{"id":"F6","shared_claims":4},{"id":"F7","shared_claims":1},{"id":"F10","shared_claims":1}],"id":"T8","label":"The comparison"},{"findings":[{"id":"F2","shared_claims":14},{"id":"F4","shared_claims":1},{"id":"F6","shared_claims":3},{"id":"F7","shared_claims":1},{"id":"F10","shared_claims":1}],"id":"T9","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F4","shared_claims":2},{"id":"F6","shared_claims":3},{"id":"F7","shared_claims":2},{"id":"F10","shared_claims":4}],"id":"T10","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-02T02:32:01.211776Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-02T02:46:58Z","record_hash":"79d19ec6d18b5a22e6b2506444918a67a4f1cd5879e3b891d9a2bec8b41d2ab0","release_hash":"a2f546dd5bc2d836fe413fb4a06e5bafc53bbc96c47b7fe7d8c8d7d2b65561c9","report_id":"erudio-nct06712316","run_id":"160ffa45-d2d4-4d3f-9ad8-a6fddd121fb1","schema_version":"5.0","slug":"rosetta-lung-02-06712316","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"ROSETTA Lung-02 tests chemotherapy combined with pumitamig as initial treatment for non-small cell lung cancer; replacing pembrolizumab–chemotherapy remains debated. The report cites 12 physicians, including 11 medical oncologists and speakers described in the sources as a trial presenter or investigator; questions also concern PD-L1-negative disease and selection biomarkers. What comparative benefit and patient-selection evidence would justify switching without avoidable toxicity for patients unlikely to benefit? The sources reviewed for this edition place the trial’s phase II results at ASCO 2026.","meta_description":"71 sources screened · 146 verified statements (70 from clinicians verified by NPI or staff page) from 31 sources · 10 findings. Updated Nov 2, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-a4691f0d0ff9a06710bd","claim-6910fa254d08c24a2ac8"],"id":"F1","paraphrase":"A medical oncologist asks on LinkedIn whether phase III testing can show greater benefit from pumitamig with chemotherapy than from pembrolizumab-based treatment.","publication_caveats":{"reason":"Publication caveats are not stated in the sources reviewed for this edition.","status":"not_set"},"source_channel":"linkedin_post","source_date":"2026-05-31","title":"Can pumitamig improve on the pembrolizumab–chemotherapy backbone?"},{"cited_claim_ids":["claim-5952f03892662df617d7"],"id":"F5","paraphrase":"In a podcast discussion, a medical oncologist asks about PD-(L)1/VEGF bispecific mechanisms and their potential benefit relative to existing immune checkpoint inhibitors.","publication_caveats":{"reason":"Publication caveats are not stated in the sources reviewed for this edition.","status":"not_set"},"source_channel":"podcast","source_date":"2026-06-09","title":"Does molecular architecture translate into clinical differences?"}]},"publication":{"approved_at":"2026-11-02T02:46:58Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":71},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on platinum-sparing alternatives, generalizability and benefit–toxicity trade-offs in first-line non-small cell lung cancer.","Not yet captured in this edition: a remark on distinguishing the trial presenter from a clinician commenting on the trial.","Not yet captured in this edition: a view on emerging first-line chemoimmunotherapy alternatives for advanced squamous non-small cell lung cancer.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","118 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","This is a qualitative account of the sources reviewed for this edition, not a representative survey or a measure of agreement among HCPs. Reposts and repeated accounts of the same presentation are not independent clinical corroboration.","Some discussions may be missing because they did not use the trial's name or recognized aliases. Some available social-media and recorded passages were not fully evaluated, including development-resource and partnership comments. Related first-line bispecific discussion and parts of the alternative ADC–immunotherapy debate, including comparator choice and benefit–toxicity judgments, are incompletely covered.","No exact-trial results publication was found and no full protocol document was available in the reviewed materials. Early commentary therefore cannot be checked here against a complete study report. The materials do not establish an exact pumitamig regulatory label.","Several response, safety and dose descriptions differ by confirmation status, subgroup, dose, event category or wording. They have not been pooled or reconciled by assumption.","Some recorded statements cannot be attributed by name. A program's guest list or a shared voice label does not establish ownership of those words.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","A speaker's contextual first-line interview includes a comparator description that differs from the dose-only phase 2 accounts. Its favorable comparisons are preserved as the speaker's assessment, not treated as a controlled ROSETTA Lung-02 treatment effect.","Cross-trial, monotherapy and class observations are identified as such. They do not establish equivalence, comparative safety or efficacy for the ROSETTA Lung-02 chemotherapy combination."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":2,"linkedin_post":2,"other":0,"podcast":3,"publication":0,"registry":0,"regulatory":0,"x_thread":22,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":31},"count":31,"evidence_window":{"end":"2026-10-25","start":"2026-03-26"},"retrieval_snapshot":"2026-11-01T22:21:06.159698Z","timeline":[{"count":2,"week":"2026-W13"},{"count":1,"week":"2026-W17"},{"count":1,"week":"2026-W19"},{"count":5,"week":"2026-W21"},{"count":14,"week":"2026-W22"},{"count":2,"week":"2026-W23"},{"count":1,"week":"2026-W24"},{"count":1,"week":"2026-W27"},{"count":1,"week":"2026-W28"},{"count":1,"week":"2026-W41"},{"count":1,"week":"2026-W42"},{"count":1,"week":"2026-W43"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT06712316:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06712316:context","quote_policy":"short_quote_link_out"},{"id":"openfda:097d166f-b73b-41d3-9b37-7653cd2a0c41:20260731","quote_policy":"short_quote_link_out"},{"id":"openfda:4c89cedc-e48b-445c-ad05-54dbe60e4fb0:20260721","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-2ldgzgkb5gn7kfn35avzn7ai-3mmgvkm2w2v2y","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-b6or56vkmhywvtt2wkcsnbsc-3mogrsuyjs22k","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-empjqd66qnuzjesut6yhsux4-3mhvybtbsgem2","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ffhfzwr3igtwt4y7zdompvjv-3mmgl35igak2j","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-m6jdnder362h5gtsemwg53wy-3mn4iqrgrv223","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-m6jdnder362h5gtsemwg53wy-3mn4km6oup22u","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-vvvhpax6mtymhk7n3qiv36af-3mmvx4eoxws2d","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7416499159949570048","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7466685599102464000","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7466862400831594496","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:1a675f","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:8c1552","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:c90e75","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1919401607520780510:062ca1f6-b0a8-4c64-b618-9ce632019f75","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1926685588238880871:5682f009-5f81-4cd1-8eaf-9b9d31114e4e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1927111647186866579:7b8ca42f-8338-4864-bf9e-4383d6239e41","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1927341426972459356:bf8dd73f-086c-4b50-8c30-a1883c59e8e6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1928363644292845659:0f56b5c1-888c-405d-a626-e40a1df44687","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1928908352874017251:7beb5e88-42e9-48d9-8d2f-7689a24b59b1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929133094105227721:ddcb11af-9a40-4c54-8cb5-e706cc1cb58f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1985353997142638855:0ed4fbdb-1a4e-473e-9d55-39d73709488c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1997424678537687187:9ec2834e-5a4b-4166-99c6-a73fd7ee5400","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1998739699809042444:ab81412e-504d-409a-80c0-46f0df3ffc7c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2014261831376719929:527bec08-6d4c-446d-9bc5-6db521594a0f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2037164652631666846:8be3dfad-5bcb-4ba8-aade-2d4250b0f733","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2037226261680898148:8ac60172-3247-4c72-8963-e26a5e484e0d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2047027228928544933:9c047849-1b1e-45d9-b7f6-46075f16b59b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2049088738916208683:9bb83238-7cbc-4b9c-8856-8e173318c573","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2051623168637366762:17ade893-3e6e-47f6-920c-5610211fcc21","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2057578832815681982:3bf980ce-11ad-40f0-b848-b7f3753cb646","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2057795592445632797:a74ee2e6-e1a9-401a-8705-1b9bd7e9697d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2057815163957604658:b9b2d300-f868-445e-96e4-0d07f747759d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2057835504931053644:c4796c55-3a64-42e1-926b-8a3b358373f4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2057850401873866893:523dab6b-e106-4fe5-aa9e-c22934b89976","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2058541022209298663:11a74fb1-607c-400f-a15e-32527b9c595c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2059964131554312315:fc1dd153-7c9f-4aba-89dd-db88c7ba5f72","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060157469720994085:edfc05e5-baf2-404e-9135-99ac782613cf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060307936048508978:5a4d0e18-dbe2-4791-a649-886e09d21d17","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060395744289235454:3fc556d6-97ff-42c3-acd1-75ff7a950ab1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060790433446236165:6312237a-5b3a-4ed6-8001-57200b1a4a14","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060790908283503067:f55ff37a-2716-4458-850b-cca52add6eac","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060791009382928506:3a1bb2cf-386a-40c4-b8a6-b58ab45b4be5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060791401831424458:6ba2ede5-65af-4558-b704-07d5f1695937","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060791607230595181:325f960c-9487-42af-989e-0f89bd448bbf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060792122962510184:491f555f-5de5-44a8-ad14-4533040df095","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060796273003995383:f0c13208-39d8-4f4a-8080-464011512425","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060798474396844110:62cf818f-a2ba-45fe-8d32-50a751824a30","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060801893731909969:34b7f30a-765e-42c5-895b-00baf0e6360a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060805296428065054:d5c257fa-0df4-455b-8f8b-bab8d973e7e3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060810761237344738:8fb97965-220b-458b-8ff8-411836596c40","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060814375548826064:50d0f41d-b1ff-47ba-be2c-bc91c0d1fcb6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060824739443032466:bac45b36-00be-4850-af8f-034c2b62bc86","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060825661800173826:be4d28b3-6dbb-40fe-97b6-9e70e1628071","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060829106565239162:db9b4ffb-07b5-4ba6-9977-60df8f465291","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060848991600873834:6be8375b-3bfe-4058-a4e7-11d9e85de064","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060863152464830652:5b18e22c-62b6-4cf9-9101-788f984eecad","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060879803889201429:0bac914e-4f66-4c98-b8ff-2046061e1db5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060919741896904709:4d38b97f-c906-4c82-aa2a-205f810713d7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061025235898339699:ce6a9807-7c2b-4e3c-b148-b9e27b962a6a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061040054563180684:783df88e-a024-462b-8f32-4bcdf1652c46","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061209195689521286:d63f4992-6139-490b-8324-5cb4358c3f63","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061304254610960815:5c357f50-8eac-46ac-812c-14aac19eb043","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061417498457600119:ee139648-7cab-4762-becb-de78d3a4b980","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2067002019085197445:7d9cd17b-5a46-4893-b273-41f444e01361","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110409007290798290:02082246-f1f7-4017-9b0f-90d3a95c5b12","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114259232568603083:a3f6df46-5631-48ac-8c0c-68a5a2a3488b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114260397104713970:35ee99c2-4b6a-4446-84cf-98ce553e1ced","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114430146740453541:ab2689cd-e18d-4ac4-a3ef-1488e4200035","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114662889021923567:c6f420e0-9c50-41d1-8c1e-fcde9b01f782","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:Pjlzhc5R0RQ","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:RKkrCCgnitg","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":7,"linkedin_post":3,"other":0,"podcast":3,"publication":0,"registry":0,"regulatory":0,"x_thread":56,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":71},"count":71,"evidence_window":{"end":"2026-10-26","start":"2025-05-05"},"retrieval_snapshot":"2026-11-01T22:21:06.159698Z","timeline":[{"count":1,"week":"2025-W19"},{"count":1,"week":"2025-W21"},{"count":5,"week":"2025-W22"},{"count":1,"week":"2025-W45"},{"count":1,"week":"2025-W49"},{"count":1,"week":"2025-W50"},{"count":1,"week":"2026-W03"},{"count":1,"week":"2026-W04"},{"count":3,"week":"2026-W13"},{"count":1,"week":"2026-W17"},{"count":1,"week":"2026-W18"},{"count":1,"week":"2026-W19"},{"count":8,"week":"2026-W21"},{"count":31,"week":"2026-W22"},{"count":3,"week":"2026-W23"},{"count":1,"week":"2026-W24"},{"count":2,"week":"2026-W25"},{"count":1,"week":"2026-W27"},{"count":1,"week":"2026-W28"},{"count":1,"week":"2026-W41"},{"count":1,"week":"2026-W42"},{"count":3,"week":"2026-W43"},{"count":1,"week":"2026-W44"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: pumitamig","status":"unmapped"},{"brand_names":["Keytruda"],"label":"pembrolizumab","slug":"pembrolizumab"},{"brand_names":["Paraplatin"],"label":"carboplatin","slug":"carboplatin"},{"brand_names":["Alimta"],"label":"pemetrexed","slug":"pemetrexed"},{"brand_names":["Taxol"],"label":"paclitaxel","slug":"paclitaxel"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"ROSETTA Lung-02","aliases":["ROSETTA Lung-02","Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)","A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer"],"brief_title":"Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)","collaborators":["Bristol-Myers Squibb"],"conditions":["Non-small Cell Lung Cancer"],"display_condition":"first-line non-small cell lung cancer","display_interventions":[["pumitamig (BNT327)"]],"enrollment":{"count":1580,"type":"ESTIMATED"},"interventions":[{"name":"Pumitamig","synonyms":["BNT327","BMS-986545","PM8002"],"type":"DRUG"},{"name":"Pembrolizumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Carboplatin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Pemetrexed","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Paclitaxel","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT06712316","official_title":"A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer","overall_status":"RECRUITING","phase":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2029-01","type":"ESTIMATED"},"primary_endpoints":[{"description":"For substudies A and B. AEs graded according to Common Terminology Criteria for Adverse Events (CTCAE v5.0) in the combination treatment regimen.","measure":"Phase 2 - Occurrence of treatment-emergent adverse events (TEAE) (including Grade ≥3), adverse events of special interest (AESIs), treatment-related TEAEs, treatment-emergent serious adverse events (SAE), and treatment-related treatment emergent SAEs","timeFrame":"From the first dose of the investigational medicinal product (IMP) to the 90-day Follow-Up Visit"},{"description":"For substudies A and B.","measure":"Phase 2 - Occurrence of dose interruption, reduction, and discontinuation of IMP due to TEAEs (including related TEAEs)","timeFrame":"From the first dose of IMP to the 90-day Follow-Up Visit"},{"description":"For substudies A and B. ORR is defined as the proportion of participants in whom a confirmed complete response (CR) or confirmed partial response (PR) (per Response Evaluation Criteria in Solid Tumors version 1.1 \\[RECIST v1.1\\] based on the investigator's assessment) is observed as best overall response.","measure":"Phase 2 - Objective response rate (ORR)","timeFrame":"Up to approximately 2 years"},{"description":"For substudies A and B. Based on investigator's tumor assessment according to RECIST v1.1.","measure":"Phase 2 - Best percentage change from baseline in tumor size","timeFrame":"Up to approximately 2 years"},{"description":"For substudies A and B. PFS defined as the time from randomization to first documented tumor progression (progressive disease per RECIST v1.1), or death from any cause, whichever occurs first.","measure":"Phase 3 - Progression free survival (PFS) assessed by BICR","timeFrame":"Up to approximately 5 years"}],"registered_date":{"date":"2024-12-02","type":"ACTUAL"},"registry_last_updated":"2026-10-15","registry_url":"https://clinicaltrials.gov/study/NCT06712316","short_name":"ROSETTA Lung-02","short_name_basis":"canonical_name","sponsor":"BioNTech SE","start_date":{"date":"2025-01-07","type":"ACTUAL"},"study_design":"interventional, randomized, sequential, phase2, phase3","study_ids":[{"id":"BNT327-06","type":"sponsor_study_id"},{"id":"2024-515764-31-00","type":"ctis"}],"study_type":"INTERVENTIONAL"}}}